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Abstract 
Cellular senescence is a tumor-suppressor mechanism that prevents the proliferation of cancerous 
cells by inducing a state of permanent cell cycle arrest. Common characteristics of senescent cells 
include abnormal cell morphology and increased expression of the cyclin-dependent kinase 
inhibitor p16. Elevated p16 expression is facilitated by the presence of senescence-associated 
heterochromatin foci (SAHF), which are formed in part by the HP1 epigenetic pathway. We have 
previously identified hepatoma-derived growth factor-related protein 2 (HRP2) as a novel protein 
of the HP1 pathway; however, little is known about its function as an epigenetic regulator. To 
better understand the role of HRP2 within the HP1 pathway, we investigated whether HRP2 
contributes to the pathway’s senescence-promoting behavior. We found that exogenous expression 
of HRP2 promotes a senescent-like phenotype in the triple-negative breast cancer cell line MDA-
MB-231, as well as the prostate cancer cell line PC3. Wound-healing analysis demonstrated that 
HRP2 infection inhibits motility of MDA-MB-231 cells, but not PC3 cells. Using CRISPR-dCas9 
technology to modulate endogenous HRP2 expression levels, we observed that endogenous HRP2 
expression is positively correlated with p16 expression in MDA-MB-231 cells. Taken together, 
these findings indicate that in certain cell lines, HRP2 acts within the HP1 pathway to form SAHF, 
promoting p16 expression and driving cells into premature senescence. A better understanding of 
the mechanistic function of HRP2 as a chromatin modulator may clarify the processes of this 
cellular stress-response pathway and lead to the development of novel therapeutics to treat diseases 







The field of epigenetics studies how chromatin dynamics affect gene expression levels without 
altering the DNA sequence. Rather than making a change to the nucleotide sequence, epigenetic 
modifications alter the folding patterns of DNA. DNA wraps around histone octamers to form 
chromatin, which exists in two different structural states: euchromatin and heterochromatin. 
Euchromatin is characterized by its loose, uncoiled structure which can be readily accessed by 
transcriptional machinery, whereas heterochromatin is more tightly compacted. As a result, genes 
found in euchromatic regions of the DNA are transcriptionally active while those found in 
heterochromatic regions are transcriptionally silent.1-3 These chromatin conformations are not 
fixed, however, meaning that segments of DNA can alternate between euchromatic and 
heterochromatic states. Structural changes of chromatin compaction occur as a result of post-
translational modifications (PTMs) made to histone tails.1,2  
 
Two of the most common types of epigenetic PTMs are acetylation and methylation. Histone 
acetylation is almost always associated with a more open and accessible chromatin state, while the 
effects of methylation on chromatin structure vary depending on the specific histone residue being 
modified.1-3 The trimethylation of histone H3 lysine 9 (H3K9me3), in particular, is known to 
induce heterochromatin formation. Methylation of this residue is often performed by the histone 
methyltransferase enzymes SUV39H1/2, SETDB1, and G9a, which function within the 
heterochromatin protein 1 (HP1) pathway.1,3 HP1 is a protein that promotes the assembly of 
heterochromatin and has three isoforms: HP1, HP1, and HP1. The chromodomain of HP1 
binds to trimethylated H3K9 residues while the chromoshadow domain recruits histone 
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methyltransferases that deposit methyl groups onto adjacent histones, leading to chromatin 
compaction and gene repression.3  
 
The dysregulation of the HP1 heterochromatin formation pathway has been implicated in 
numerous cancers including pancreatic, uterine, prostate, and breast cancer.3,4 This suggests that 
the HP1 pathway has a role in preventing cancer progression. In fact, HP1 has been shown to 
contribute to the tumor suppressor activity of the p16/pRb pathway. The p16/pRb pathway is 
responsible for repressing proliferative genes such as E2F target genes. In order to stably repress 
these cell cycle promoting genes, senescence-associated heterochromatin foci (SAHF) are formed. 
H3K9me3 and bound HP1 proteins are known molecular markers of SAHF and they maintain the 
transcriptionally silent state of proliferative genes. This forces cells into a state of permanent cell 
cycle arrest known as senescence.5,6 Senescent cells possess characteristic morphological traits 
such as a flattened-shape, vacuole accumulation, increased granularity, and vanished borders. 
Senescent cells are also commonly large in size and multinucleate. Aside from their distinct 
morphological traits, senescent cells also experience in increase in the expression of the tumor 
suppressor p16.5,6 
 
The relevance of HP1 and HP1-associated proteins to maintaining genomic stability and thus 
preventing cancer has been well-established, making the pathway a promising target for cancer 
therapeutics. However, the function of these proteins remains poorly understood. We have 
previously demonstrated that an inhibitor of the HP1 pathway interacts with M-phase 
phosphoprotein 8 (MPP8), as well as a novel protein known as hepatoma-derived growth factor-
related protein 2 (HRP2), to prevent heterochromatin formation.3 MPP8 has been identified as a 
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part of the HUSH complex, another epigenetic complex that mediates heterochromatin formation 
through H3K9me3 deposition.7 MPP8 has also been shown to promote epithelial-to-mesenchymal 
transition, which causes a change in cell morphology and motility that favors metastasis in cancer. 
In particular, MPP8 has demonstrated an ability to enhance tumor cell motility and invasion in the 
triple-negative breast cancer cell line MDA-MB-231.8 In contrast to MPP8, literature on HRP2 as 
an epigenetic regulator is lacking.  
 
To better understand the role of HRP2 within the HP1 heterochromatin formation pathway, we 
investigated whether HRP2 can promote cellular senescence. We adapted prior studies of MPP8 
to determine the effect of HRP2 expression on tumor cell morphology and motility in the MDA-
MB-231 cell line. We then extended our studies to the metastatic prostate cancer cell line PC3 to 
investigate whether our results could be applied to other forms of cancer. Additionally, we used a 
nuclease-deficient form of Cas9 (dCas9), fused to the epigenetic regulator KRAB, to modify HRP2 
expression levels and examine the effect on p16 expression.9,10 Our studies suggest that HRP2 
works as a part of the HP1 pathway to establish SAHF in triple-negative breast cancer cells, leading 
to premature senescence. 
 
Methods 
Cell Lines and Tissue Culture 
Metastatic breast cancer (MDA-MB-231) cells were grown in DMEM (Corning) supplemented 
with HEPES buffer (Corning), MEM NEAA (Gibco), penicillin-streptomycin (Corning), 2-
mercaptoethanol (Gibco), and 10% fetal bovine serum (Atlanta Biologicals). Cells were lifted 
using 0.05% trypsin (Gibco). The same treatment was applied to 293TX cells. Metastatic prostate 
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cancer (PC3) cells were grown in DMEM supplemented with 10% fetal bovine serum and 
penicillin-streptomycin. Cells were lifted using 0.25% trypsin (Gibco). 
 
Transfection 
All 293TX cells (Clontech) were transfected with lentivirus plasmids N74 and N75 (N74, pMD2.G 
(VSV-G envelope expressing plasmid); Addgene #12259; N75, psPAX2 (2nd generation lentiviral 
packaging plasmid); Addgene #12260) for subsequent lentiviral harvesting and infection. For the 
wound-healing assay, cells were also transfected with either HRP2WT, HRP2PWWP, HRP2IBD, or 
a BFP control. HRP2PWWP and HRP2IBD are mutated forms of HRP2 in which the PWWP domain 
and integrase binding domain (IBD), respectively, have been removed from the protein through 
gene cloning (Fig. 1). For the western blot analysis, cells were transfected with either dCas9-
KRAB, HRP2-targeting sgRNA, a non-targeting gRNA, or HRP2WT. To transfect the 293TX cells, 
a solution of 4.5 µg N74, 13.5 µg N75, 1.8 mL OptiMEM, 108 µL of polyethyleneimine, and 18 
µg of DNA was added dropwise to each respective plate of cells. Successful transfection was 
indicated by blue fluorescence in the BFP control cell lines. Media was changed approximately 16 
h after transfection. Cells could then be used for lentiviral harvesting and infection 48 h after 







Figure 1. Depiction of HRP2 constructs. HRP2WT contains full length human HRP2. HRP2PWWP 
is a truncation removing the first 125 amino acids of HRP2, containing the PWWP domain. 





Cells were plated in 12-well plates 24 h prior to infection. For the infection of the MDA-MB-231 
and PC3 cell lines, 5.0104 and 7.5x104 cells were plated per well, respectively. Before infection, 
all materials were sterilized with ultraviolet light for approximately 15 min. To begin, the 
supernatant from the previously transfected cells was transferred from each plate to separate 
conicals and centrifuged at 1000 rpm for 5 min. The resulting supernatant from the centrifuged 
conicals was then transferred to its respective ultracentrifuge tube. The ultracentrifuge tubes 
were balanced and spun in the Beckman Coulter Optima XPN-80 ultracentrifuge under a vacuum 
at 20,000 rpm at 4 ºC for 2.5 h. An hour before infection, the media of the cells to be infected 
was replaced with a polybrene mixture. The MDA-MB-231 cell line received 1 µL polybrene/1 
mL of media while the PC3 cell line received 0.75 µL polybrene/1.5 mL of media. After 
ultracentrifuging, the supernatant from each ultracentrifuge tube was carefully aspirated, with 
only the viral pellet remaining. The pellet was resuspended in 1X PBS (Corning) and then 
transferred to its respective microfuge tube. The ultracentrifuge tube was washed with 1X PBS 
and again transferred to its respective microfuge tube. All microfuge tubes were spun down at 
top speed, around 30,130 xg, and resuspended. The microfuge tubes were then allowed to shake 
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at 300 rpm for 10 min and resuspended again. Each well of the 12-well plate was then infected 
by its respective sample. The MDA-MB-231 cells received a concentration of 5 µL and 15 µL of 
each construct, with the exception of the HRP2WT construct, which included a 30 µL dose. The 
PC3 line received a concentration of 5 µL and 20 µL of each construct. The plate of infected 
cells was then parafilmed and spun at 1000 xg for 25 min at room temperature. After spinning, 
the parafilm was removed and the cells incubated at 37 ºC. Cells incubated for 48 h following 
infection by changing media without selection. Successfully infected cells were then selected for 
by treating BFP control cells with blasticidin and HRP2WT, HRP2PWWP, and HRP2IBD cells 
with puromycin. After the media on the infected cells had been changed three times, the cells 
were no longer considered to be infectious and could be used for the wound-healing assay. The 
same infection procedure was followed for the infection of MDA-MB-231 cells with either 12.5 
µL of dCas9-KRAB, 12.5 µL of dCas9-KRAB and 12.5 µL of non-targeting sgRNA, 12.5 µL of 
dCas9-KRAB and 12 µL of HRP2-targeting sgRNA, or 5 µL of HRP2WT to be used for the 
western blot analysis. 
 
Wound-Healing Assay 
Each cell type was plated in triplicate in 6-well plates. Once cells had grown to a confluent 
monolayer, media was aspirated from the wells, changing tips between each construct. Using a 
p200 pipette tip, the well was scratched from end-to-end down the middle of the well. Each well 
was washed twice with 1 mL of 1X PBS and aspirated to minimize the amount of cell debris left 
from the scratch. Finally, each well received 2 mL of fresh media. Images were taken immediately 
after scratching using CellSens imaging software connected to an Olympus IX71 microscope at 
10X in phase. At 24 and 48 h after scratching, wells were washed twice with 1X PBS and media 
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was replaced before taking subsequent images. CellSens software was additionally utilized in order 
to quantify the size of the wound.  
 
Western Blot Sample Prep 
Media was aspirated off of a 15 cm plate of MDA-MB-231 cells and washed with 10 mL 1X PBS. 
The PBS was then aspirated away and replaced with 3 mL of 0.05% trypsin-EDTA, then left to 
incubate at 37 ºC for 8 min, agitating the plate halfway. To quench and resuspend the cells, 10 mL 
of media was added to the plate and then transferred to a 15 mL conical, which was then 
centrifuged at 1000 rpm for 5 min. The resulting supernatant was aspirated away and the pellet 
was resuspended in 1 mL of 1X PBS, then transferred to a sterile microfuge tube and centrifuged 
at 1500 rpm for 5 min. This step was repeated a second time, and the supernatant was aspirated 
away. Each tube received 1.5 mL of M-PER lysis buffer and was pipetted to resuspend the cells. 
The mixture then received 3 µL of benzonase (Sigma-Aldrich) and 3 µL of protease inhibitor 
cocktail (Active Motif) and was inverted to mix. The mixed samples were left in a 37 ºC water 
bath for 10 min, then inverted at room temperature for 20 min. The supernatant was then 
transferred to a new microfuge tube and centrifuged at top speed for 5 min. 
 
Western Blot and Gel Transfer 
Before running the gel, 7.5 µL of 2X laemmli SDS-loading dye (Bio-Rad) was added to each 10 
µg sample, along with BME. The samples were boiled for 2-5 min at 95 ºC, then centrifuged at 
top speed for 1-2 min. Each well of the gel received 15 µL of its respective sample, and the gel ran 
at 200 V for 40 min. After running the western, a gel transfer was performed using 1X tris-glycine 
transfer buffer (Bio-Rad), and the transfer ran for 1 h at 100 V. 
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Detection with Antibodies 
Transfer membranes were placed in blocking buffer and rocked at 4 ºC for 1 h. The blocking buffer 
was removed and the primary antibody was added 1:1000 in PBST to its respective membrane. 
Primary antibodies used for HRP2 and p16 were 15134-1-AP (Proteintech) and ab108349 
(Abcam), respectively. After rocking at 4 ºC at low speed overnight, the primary antibody was 
removed and the transfer membranes were washed four times with 5 mL of PBST for 5 min. Fresh 
secondary antibody was prepared by adding 3.3 µL of IRDye 800CW Goat anti-Rabbit 925-32211 
(Li-Cor) to 40 mL of PBST, with 40 µL of 10% SDS to reduce background. The reaction occurred 
away from light exposure. The secondary antibody was added to the membranes and rocked at 
room temperature at low speed for 1 h. The membranes were washed 4 times with 5 mL of PBST 
for 5 min each and then imaged with Li-Cor imaging software. 
 
Results 
Infection with HRP2 Impacts Cell Morphology 
Upon infection with HRP2WT, the MDA-MB-231 cell line exhibited an atypical cell morphology 
that resembles senescent cells. Wildtype MDA-MB-231 cells have a more condensed, slender 
shape whereas the infected cells appeared flattened and splayed out. Some cells also exhibited a 
multinucleate phenotype, increased granularity, and vacuole accumulation. This abnormal 
phenotype was observed in the HRP2WT (Fig. 2, B), and in HRP2PWWP, and HRP2IBD infected 
cell lines (data not shown) at all concentrations, though higher concentrations corresponded to 
more dramatic phenotypes. A similar effect on cell morphology was observed in PC3 cell lines 
infected with the HRP2WT (Fig. 2, D), HRP2PWWP, and HRP2IBD (data not shown). No change in 
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morphology was observed in BFP-infected control cells in either cell line, indicating that the 
senescent-like phenotype was not a result of lentiviral infection. 
 
           
 
           
 
Figure 2. Infection with HRP2WT induces senescent-like morphology in MDA-MB-231 and PC3 cell 
lines. Phenotypic cell morphologies observed in a) WT MDA-MB-231, b) HRP2WT 15 µL MDA-MB-231, c) 
WT PC3, and d) HRP2WT 15 µL PC3 cells. Some HRP2WT 15 µL infected cells display a large, flattened 
shape, vacuole accumulation, multiple nuclei, and increased granularity. Arrowheads indicate 
representative cells of senescent-like morphology, particularly those exhibiting a flattened shape. 
 
Infection with HRP2 Impairs Wound-Healing 
In all three trials, the wound-healing assays of the MDA-MB-231 cell lines revealed that cell 
motility was significantly hindered in cells infected with HRP2WT, exhibited by a reduced change 
in wound size compared to wildtype cells. Most cells infected with truncated HRP2 also 
experienced a smaller change in wound size compared to control cells throughout all trials, 






µL BFP-infected controls were able to completely close the wound in the first wound-healing trial 
of the MDA-MB-231 cells, indicating that lentiviral infection is not the source of the observed 
change in motility (data not shown). These trends were not observed in the PC3 wound-healing 
assays. PC3 cells infected with HRP2WT or HRP2 truncations failed to modify wound size 





















      
 
        
 
      
 
  
Figure 3. Infection with HRP2WT inhibits cell motility in MDA-MB-231 cell line. Wound size measured 
by red line. a-c) Wound healing images of uninfected MDA-MB-231 cells from Trial 3 at 0, 24, and 50 h, 
respectively. Wound size measured to be (a) 958.35 µm (b) 761.16 µm and (c) 521.96 µm.  d-f) Wound 
healing images of HRP2WT 30 µL MDA-MB-231 cells from Trial 3 at 0, 24, and 50 h, respectively. Would 
size measured to be (d) 976.35 µm (e) 813.95 µm and (f) 607.71 µm. g-i) Total change in wound size over 
24 h; n=3; t-test between indicated sample and uninfected control, *p<0.0332, **p<0.0021. Note that 
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Figure 4. Infection with HRP2WT does not significantly alter cell motility in PC3 cell line. Wound size 
measured by red line. a-b) Wound healing images of uninfected PC3 cells at 0 and 48 h, respectively. 
Wound size measured to be (a) 802.84 µm and (b) 553.12 µm. c-d) Wound healing images of HRP2WT 20 
µL PC3 cells at 0 and 48 h, respectively. Wound size measured to be (c) 816.76 µm and (d) 708.01 µm. e) 
Total change in wound size at 24 h in MDA-MB-231 cells; n=3; test between indicated sample and 
uninfected control, *p<0.0332, **p<0.0021 f) Total change in wound size at 24 h in PC3 cells; n=3; t-test 












HRP2 Expression is Positively Correlated with p16 Expression 
To investigate whether HRP2 could promote p16 expression to contribute to the SAHF-forming 
function of the HP1 pathway, we utilized the CRISPR-dCas9 system fused with KRAB to modify 
HRP2 expression. We then analyzed the effect on p16 expression through western blots. The gels 
show that HRP2 is normally expressed in the MDA-MB-231 cell line, although not at levels 
capable of inducing p16 expression (Fig. 5A & B, lanes 1-3). They also demonstrate that our 
dCas9-KRAB fusion and HRP2-targeting sgRNA upregulated endogenous HRP2 expression (Fig. 
5A, lane 4), and that this increased expression is sufficient to initiate p16 expression in the MDA-
MB-231 cell line (Fig. 5B, lane 4). Interestingly, cells infected with 5 µL HRP2WT did not induce 
p16 expression (Fig 5B, lane 5).  
 
Figure 5. Expression of endogenous HRP2 is positively correlated with p16 expression. Western blots 
stainging for (a) HRP2 or (b) p16,  performed from MDA-MB-231 cells with the following constructs: (1) 
Uninfected (2) dCas9-KRAB (3) dCas9-KRAB + nontargting sgRNA (4) dCas9-KRAB + HRP2-targeting 




The senescence of cells under oncogenic stress occurs partially through the formation of 
senescence-associated heterochromatin foci, facilitated by the HP1 pathway.5,6 Here we 
investigated whether HRP2, a newly discovered epigenetic regulator, contributed to the 
senescence-promoting function of the pathway. Lentiviral infection of HRP2WT into the metastatic 
triple-negative breast cancer line MDA-MB-231 led to an abnormal morphology resembling 
A B 
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senescent cells. Specifically, the cells became flattened, multinucleate, granular, and accumulated 
a number of vacuoles (Fig. 2). In addition to inducing a change in cell morphology, HRP2WT also 
inhibited cell motility in the MDA-MB-231 cell line. The expression of mutant HRP2 seems to 
mitigate the effects that HRP2WT has on the morphology and motility of the cells (Fig. 3). This is 
likely due to the deletion of either the PWWP or IBD domains, which are highly conserved 
domains thought to support essential evolutionary functions.11 By the third wound-healing trial of 
the MDA-MB-231 cell line, the difference between HRP2WT cell motility and that of its truncations 
became less apparent (Fig. 3). Cells from each trial were re-plated and used again for subsequent 
wound-healing assays, so this lack of distinction may be a result of regular aging.  
 
To determine whether the effect of HRP2 on cell morphology and motility could be observed in 
other cell lines, we repeated the lentiviral infection and wound-healing assays in the metastatic 
prostate cancer line known as the PC3 cell line. Interestingly, while HRP2WT expression did induce 
a similar morphological change in the PC3 cells, there was no significant change in cell motility 
between the uninfected negative control, BFP-infected control, and experimental samples (Fig. 2 
& 4). This suggests that the role of HRP2 in promoting cellular senescence may be specific to the 
stress response of triple-negative breast cancer lines like MDA-MB-231. A better understanding 
of which cancer lines HRP2 can induce a significant response in may allow for the development 
of more patient-specific therapies to cancer and is an area for future study. 
 
After determining that the effect of HRP2 is most pronounced in the MDA-MB-231 line, we 
continued our analysis of HRP2 as a possible contributor in senescence stress response. We utilized 
CRISPR-dCas9 fused with KRAB to target the HRP2 locus and modulate endogenous HRP2 
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expression. We then performed western blots staining for HRP2 and p16, a tumor-suppressor often 
highly expressed in senescent cells. Western blot data demonstrates that upregulation of 
endogenous HRP2 induces p16 expression (Fig. 5). These results support our hypothesis that 
HRP2 functions within the HP1 pathway to induce senescence.  
 
Our results are consistent with previous literature that demonstrate HP1 and its associated proteins 
are markers of senescence induced by oncogenic stress, particularly through the formation of 
senescence-associated heterochromatin foci.5,6 We show that infection with HRP2WT leads to the 
development of senescent-like morphology and impaired cell motility of the triple-negative breast 
cancer line MDA-MB-231, and that endogenous HRP2 and p16 expression levels are positively 
correlated in the same line. However, it is important to note that one drawback of the wound-
healing assay employed in this study is the difficulty to distinguish cell migration into the wound 
from cell proliferation. While we were able to qualitatively observe that the confluency of each 
well remained consistent over the 48 h imaging period, this can and should be confirmed in the 
future by incorporating lineage-tracing through a fluorescent label. A fluorescent label that can be 
distributed at a constant dilution level with each cell division allows for the tracking of both cell 
proliferation and cell migration in the wound-healing assay to avoid conflating the two 
variables.12,13 Additionally, it remains unclear why exogenous expression of HRP2 did not also 
induce p16 expression in our western blot analysis. Further exploration of the relationship between 
HRP2 and p16 may uncover these details. 
 
While our findings support the hypothesis that HRP2 promotes senescence, it is still not clear how 
HRP2 is functioning mechanistically. Further studies will seek to clarify the molecular interactions 
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involved in HRP2-induced senescence. In particular, we are interested in the localization patterns 
of HRP2 to E2F target genes and to SAHF. It is also unknown how HRP2 interacts with HP1- and 
other SAHF-associated proteins. Exploring the protein-protein interactions of HRP2 and its 
localization on chromatin may elucidate more about how this protein functions within the HP1 
pathway and identify potential drug targets for the treatment of certain cancers. 
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